HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
25 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
TUBB6
tubulin beta 6 class V
Chromosome 18 · 18p11.21
NCBI Gene: 84617Ensembl: ENSG00000176014.13HGNC: HGNC:20776UniProt: B3KS31
212PubMed Papers
21Diseases
87Drugs
2Pathogenic Variants
RESEARCH IMPACT
Trending
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
nucleusprotein bindingextracellular exosomemicrotubulenon-small cell lung carcinomabreast cancerneoplasmbreast neoplasm
✦AI Summary

TUBB6 encodes tubulin beta 6 class V, a structural component of microtubules that plays specialized roles in cellular differentiation, migration, and pathological processes. As a microtubule constituent, TUBB6 forms heterodimers with alpha-tubulin to create the cylindrical structures essential for cytoskeletal organization 1. TUBB6 expression is particularly elevated in osteoclasts, where it is essential for podosome organization and sealing zone formation required for bone resorption activity 1. The protein also facilitates cellular migration and invasion, as demonstrated in bladder cancer where TUBB6 promotes muscle invasion and correlates with poor prognosis 2. In ocular diseases, TUBB6 drives pathological angiogenesis through the WNT3A-FZD8 pathway, with YBX1 regulating its mRNA stability 3. During muscle regeneration, TUBB6 upregulation contributes to microtubule reorganization, though chr18 elevation may contribute to dystrophic pathology 4. Additionally, TUBB6 functions as a long non-coding RNA in neuroprotection, activating the Nrf2 pathway to suppress inflammation and ferroptosis after traumatic brain injury 5. The gene has also been associated with focal segmental glomerulosclerosis 6 and ocular congenital cranial dysinnervation disorders 7, highlighting its diverse roles in development and disease.

Sources cited
1
TUBB6 forms heterodimers with alpha-tubulin and is essential for osteoclast podosome organization and bone resorption
PMID: 32265273
2
TUBB6 promotes cellular migration and invasion in bladder cancer and correlates with poor prognosis
PMID: 36054443
3
TUBB6 drives pathological ocular angiogenesis through WNT3A-FZD8 pathway with YBX1 regulation
PMID: 40083923
4
TUBB6 upregulation contributes to microtubule reorganization during muscle regeneration
PMID: 30535187
5
TUBB6 functions as lncRNA in neuroprotection by activating Nrf2 pathway
PMID: 38030103
6
TUBB6 shows differential expression in focal segmental glomerulosclerosis
PMID: 39519211
7
TUBB6 variants are associated with ocular congenital cranial dysinnervation disorders
PMID: 39033378
Disease Associationsⓘ21
non-small cell lung carcinomaOpen Targets
0.61Moderate
breast cancerOpen Targets
0.60Moderate
neoplasmOpen Targets
0.60Moderate
breast neoplasmOpen Targets
0.60Moderate
breast carcinomaOpen Targets
0.60Moderate
goutOpen Targets
0.59Moderate
Hodgkins lymphomaOpen Targets
0.58Moderate
multiple myelomaOpen Targets
0.58Moderate
familial Mediterranean feverOpen Targets
0.58Moderate
cervical cancerOpen Targets
0.58Moderate
prostate cancerOpen Targets
0.58Moderate
diffuse large B-cell lymphomaOpen Targets
0.58Moderate
head and neck malignant neoplasiaOpen Targets
0.57Moderate
lymphomaOpen Targets
0.57Moderate
stomach neoplasmOpen Targets
0.57Moderate
prostate neoplasmOpen Targets
0.56Moderate
gastric cancerOpen Targets
0.56Moderate
adenocarcinomaOpen Targets
0.56Moderate
head and neck neoplasiaOpen Targets
0.56Moderate
pancreatic neoplasmOpen Targets
0.55Moderate
Facial palsy, congenital, with ptosis and velopharyngeal dysfunctionUniProt
Pathogenic Variants2
NM_032525.3(TUBB6):c.1153T>A (p.Phe385Ile)Likely pathogenic
Ptosis
★☆☆☆2023→ Residue 385
NM_032525.3(TUBB6):c.1181T>C (p.Phe394Ser)Pathogenic
Facial palsy, congenital, with ptosis and velopharyngeal dysfunction
☆☆☆☆2017→ Residue 394
View on ClinVar ↗
Drug Targets87
ABT-751Phase II
Tubulin beta inhibitor
AGS-16C3FPhase II
Tubulin disrupting agent
renal cell carcinoma
ANETUMAB RAVTANSINEPhase II
Tubulin inhibitor
malignant pleural mesothelioma
ANG1005Phase II
Tubulin inhibitor
ANVATABART OPADOTINPhase II/III
Tubulin inhibitor
HER2 Positive Breast Carcinoma
APRUTUMAB IXADOTINPhase I
Fibroblast growth factor receptor 2 binding agent
cancer
ASG-5MEPhase I
Choline transporter-like protein 4 binding agent
Malignant Pancreatic Neoplasm
AVE-9633Phase I
Myeloid cell surface antigen CD33 binding agent
myeloid leukemia
AZINTUXIZUMAB VEDOTINPhase I
SLAM family member 7 binding agent
multiple myeloma
BELANTAMAB MAFODOTINApproved
Tumor necrosis factor receptor superfamily member 17 binding agent
multiple myeloma
BIIB-015Phase I
Teratocarcinoma-derived growth factor 1 binding agent
BIVATUZUMAB MERTANSINEUNKNOWN
Tubulin inhibitor
BMS-275183Phase II
Tubulin stabiliser
BRENTUXIMAB VEDOTINApproved
Tubulin inhibitor
CABAZITAXELApproved
Tubulin inhibitor
prostate cancer
CANTUZUMAB MERTANSINEPhase II
Tubulin inhibitor
non-small cell lung carcinoma
CANTUZUMAB RAVTANSINEPhase II
Mucin-1 binding agent
stomach neoplasm
COLCHICINEApproved
Tubulin inhibitor
familial Mediterranean fever
COLTUXIMAB RAVTANSINEPhase II
Tubulin inhibitor
diffuse large B-cell lymphoma
CROLIBULINPhase I/II
Tubulin inhibitor
DAVUNETIDEPhase III
Tubulin stabiliser
Cognitive impairment
DENINTUZUMAB MAFODOTINPhase II
B-lymphocyte antigen CD19 binding agent
diffuse large B-cell lymphoma
DEPATUXIZUMAB MAFODOTINPhase III
Epidermal growth factor receptor erbB1 binding agent
glioblastoma multiforme
DISITAMAB VEDOTINPhase III
Receptor tyrosine-protein kinase erbB-2 binding agent
breast cancer
DOCETAXELApproved
Tubulin inhibitor
DOCETAXEL ANHYDROUSApproved
Tubulin stabiliser
prostate cancer
DOLASTATIN-10Phase II
Tubulin inhibitor
ENAPOTAMAB VEDOTINPhase I/II
Tyrosine-protein kinase receptor UFO binding agent
ENFORTUMAB VEDOTINApproved
Nectin-4 binding agent
EPOTHILONE DPhase II
Tubulin stabiliser
breast cancer
ERIBULINApproved
Tubulin inhibitor
breast cancer
ERIBULIN MESYLATEApproved
Tubulin inhibitor
breast cancer
FOSBRETABULINPhase III
Tubulin disrupting agent
thyroid cancer
FOSBRETABULIN DISODIUMPhase II
Tubulin inhibitor
neuroendocrine carcinoma
FOSBRETABULIN TROMETHAMINEPhase II/III
Tubulin disrupting agent
ovarian cancer
GLEMBATUMUMAB VEDOTINApproved
Transmembrane glycoprotein NMB binding agent
lymphoma
IMGN-388Phase I
Vitronectin receptor alpha binding agent
INDATUXIMAB RAVTANSINEPhase II
Syndecan-1 binding agent
multiple myeloma
INDIBULINPhase II
Tubulin inhibitor
INDUSATUMAB VEDOTINPhase II
Heat-stable enterotoxin receptor binding agent
IXABEPILONEApproved
Tubulin inhibitor
breast cancer
KOS-1584Phase II
Tubulin stabiliser
non-small cell lung carcinoma
LADIRATUZUMAB VEDOTINPhase II
Zinc transporter ZIP6 binding agent
breast cancer
LAROTAXELPhase III
Tubulin stabiliser
urinary bladder carcinoma
LEXIBULINPhase II
Tubulin inhibitor
glioblastoma multiforme
LIFASTUZUMAB VEDOTINPhase II
Sodium-dependent phosphate transport protein 2B binding agent
ovarian cancer
LORVOTUZUMAB MERTANSINEPhase II
Neural cell adhesion molecule 1 binding agent
MECBOTAMAB VEDOTINPhase II
Tyrosine-protein kinase receptor UFO binding agent
ovarian cancer
MILATAXELPhase II
Tubulin inhibitor
MIRVETUXIMAB SORAVTANSINEApproved
Folate receptor alpha binding agent
ovarian cancer
MLN-2704Phase I/II
Glutamate carboxypeptidase II binding agent
prostate cancer
OMBRABULINPhase III
Tubulin inhibitor
sarcoma
PACLITAXELApproved
Tubulin inhibitor
PACLITAXEL DOCOSAHEXAENOIC ACIDPhase III
Tubulin stabiliser
non-small cell lung carcinoma
PACLITAXEL POLIGLUMEXApproved
Tubulin stabiliser
neoplasm
PATUPILONEPhase III
Tubulin stabiliser
PF-06263507Phase I
Tubulin inhibitor
PINATUZUMAB VEDOTINPhase II
CD22 binding agent
diffuse large B-cell lymphoma
PLINABULINPhase III
Tubulin inhibitor
non-small cell lung carcinoma
PLOCABULINPhase II
Tubulin inhibitor
colorectal cancer
POLATUZUMAB VEDOTINApproved
Tubulin inhibitor
diffuse large B-cell lymphoma
PRALUZATAMAB RAVTANSINEPhase II
Tubulin inhibitor
neoplasm
RG-7598Phase I
Fc receptor-like protein 5 binding agent
multiple myeloma
RG-7600Phase I
Tubulin inhibitor
ovarian cancer
RG-7636Phase I
Tubulin inhibitor
melanoma
RG-7841Phase I
Lymphocyte antigen 6E binding agent
SAGOPILONEPhase II
Tubulin stabiliser
breast cancer
SAR-566658Phase II
Tubulin inhibitor
triple-negative breast cancer
SOBLIDOTINPhase II
Tubulin inhibitor
SOFITUZUMAB VEDOTINPhase I
Mucin-16 binding agent
fallopian tube cancer
T-900607Phase II
Tubulin disrupting agent
hepatocellular carcinoma
TELISOTUZUMAB VEDOTINPhase III
Hepatocyte growth factor receptor binding agent
non-small cell lung carcinoma
TISOTUMAB VEDOTINApproved
Coagulation factor III binding agent
cervical cancer
TRASTUZUMAB BOTIDOTINPhase III
Tubulin inhibitor
HER2 Positive Breast Carcinoma
TRASTUZUMAB EMTANSINEApproved
Receptor protein-tyrosine kinase erbB-2 binding agent
TUSAMITAMAB RAVTANSINEPhase III
Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
non-small cell lung carcinoma
VANDORTUZUMAB VEDOTINPhase I
Metalloreductase STEAP1 binding agent
prostate cancer
VERUBULINPhase II
Tubulin disrupting agent
VINBLASTINEApproved
Tubulin inhibitor
VINBLASTINE SULFATEApproved
Tubulin inhibitor
lymphoma
VINCRISTINEApproved
Tubulin inhibitor
VINCRISTINE SULFATEApproved
Tubulin inhibitor
VINFLUNINEApproved
Tubulin inhibitor
VINFLUNINE DITARTRATEApproved
Tubulin inhibitor
benign urinary system neoplasm
VINORELBINEApproved
Tubulin inhibitor
VINORELBINE TARTRATEApproved
Tubulin inhibitor
VORSETUZUMAB MAFODOTINPhase I
Tubulin inhibitor
renal cell carcinoma
Related Genes
TUBB8BShared pathway100%CCT2Protein interaction100%DYNC1I1Protein interaction97%GJA1Protein interaction97%MAPTProtein interaction97%TUBA1AProtein interaction97%
Tissue Expression6 tissues
Heart
100%
Lung
65%
Ovary
46%
Bone Marrow
29%
Brain
15%
Liver
8%
Gene Interaction Network
Click a node to explore
TUBB6TUBB8BCCT2DYNC1I1GJA1MAPTTUBA1A
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q9BUF5
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
0.83LoF Tolerant
pLIⓘ
0.01Tolerant
Observed/Expected LoF0.54 [0.36–0.83]
RankingsWhere TUBB6 stands among ~20K protein-coding genes
  • #1,971of 20,598
    Most Researched212 · top 10%
  • #64of 1,025
    FDA-Approved Drug Targets25 · top 10%
  • #4,240of 5,498
    Most Pathogenic Variants2
  • #7,019of 17,882
    Most Constrained (LOEUF)0.83
Genes detectedTUBB6
Sources retrieved25 papers
Response time—
📄 Sources
25▼
1
YBX1-driven TUBB6 upregulation facilitates ocular angiogenesis via WNT3A-FZD8 pathway.
PMID: 40083923
Theranostics · 2025
1.00
2
Identification of Genes Associated with Familial Focal Segmental Glomerulosclerosis Through Transcriptomics and In Silico Analysis, Including
PMID: 39519211
Int J Mol Sci · 2024
0.90
3
Expanding the genetics and phenotypes of ocular congenital cranial dysinnervation disorders.
PMID: 39033378
Genet Med · 2025
0.80
4
Identifying hub genes in response to ustekinumab and the impact of ustekinumab treatment on fibrosis in Crohn's disease.
PMID: 38840917
Front Immunol · 2024
0.72
5
Quantitative proteomics identifies TUBB6 as a biomarker of muscle-invasion and poor prognosis in bladder cancer.
PMID: 36054443
Int J Cancer · 2023
0.70